Business Context and Reporting Period
This Form 8-K is a current report filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on July 15, 2019. The filing serves as a Regulation FD disclosure regarding the release of a press release and a Company Presentation to shareholders and investors. These materials were issued in preparation for a roadshow targeting investment institutions, analysts, and shareholders in New York City.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is informational regarding a corporate event and does not contain a financial statement or quarterly results summary.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The primary event is the distribution of investor presentation materials.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing explicitly states that the press release and Company Presentation contain forward-looking statements regarding future performance, which are based on reasonable assumptions but are not guarantees.
- Risks and Uncertainties: The Company directs investors to its Annual Report on Form 10-K for the year ended December 31, 2018, for a discussion of risks and uncertainties that could cause actual results to differ materially from expectations.
- Disclaimer: The Company disclaims any obligation to update or revise forward-looking statements.
Investor Verification Checklist
- Verify the specific content of the attached Press Release (Exhibit 99.1) and Company Presentation (Exhibit 99.2) for detailed strategic updates.
- Review the Form 10-K for the year ended December 31, 2018 to understand the historical financial position and risk factors referenced in this filing.
- Confirm the company name is Trovagene, Inc. (Ticker: TROV), as the input metadata incorrectly identified the registrant as Cardiff Oncology, Inc.